• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Rinat Neuroscience Selects Invivodata's Electronic Patient Diary System for Use in Osteoarthritis Study

Posted on: Monday, 27 February 2006, 09:00 CST

invivodata inc., the industry leader in electronic patient reported outcomes (ePRO) solutions for global clinical research, today announced that Rinat Neuroscience Corp. has selected its handheld ePRO system, DiaryPRO(TM), for use in a large clinical study of patients with moderate to severe pain due to osteoarthritis of the knee.

Rinat will use DiaryPRO to capture the daily frequency and severity of pain during this phase II clinical trial. Rinat will determine whether RN624, a first-in-class monoclonal antibody that inhibits Nerve Growth Factor, meets the trial's primary efficacy objective of pain and functionality improvements in osteoarthritis.

"After conducting a thorough competitive review, we selected invivodata(R) because it is best suited to meet our overall program objectives," said Franz Hefti, executive vice president of development at Rinat.

"Rinat is truly a pioneer in developing safe and effective treatments for central nervous system diseases and disorders," said Doug Engfer, president and CEO of invivodata. "We are excited to be a part of the work it is doing and look forward to forming a long-term relationship with the company as it addresses the significant unmet medical needs in pain."

About invivodata inc.

invivodata (www.invivodata.com) combines behavioral science, information technology and clinical expertise to capture the highest-quality electronic Patient Reported Outcome (ePRO) data in clinical research. The invivodata solution, which includes DiaryPRO for real-time PRO data collection and SitePRO(TM) for site-based PRO data collection, is based on patented compliance methods which include a proven patient management system that gives researchers and sponsors visibility into study progress and improves trial efficiencies. Strengthened by its regulatory and scientific expertise, invivodata is the industry-leading eDiary provider for delivering primary efficacy data for FDA approvals. Its solutions have been used in 140 clinical trials worldwide by more than 55,000 patients, collecting over 89 million patient-initiated entries for studies in over 65 disease states. invivodata's scalable business model enables it to satisfy diverse client needs and meet the increasing global demand for its innovative solutions. invivodata inc. is a privately held company with global headquarters in Pittsburgh, Pa., USA; its European headquarters are in London, England; and its technology development center is in Scotts Valley, Calif., USA.

About Rinat Neuroscience

Rinat Neuroscience Corporation, a private company based in South San Francisco, California, is a leader in the development of neuroscience-based protein therapeutics. Rinat's lead program, RN624, is entering phase 2 trials for osteoarthritis pain, and Rinat plans to initiate phase 1 clinical trials for RN1219 for Alzheimer's disease this calendar quarter. Rinat's third development program will be for migraine prophylaxis. For more information on Rinat, please visit www.rinatneuro.com.

Source: Business Wire

More News in this Category